Skip to content
Trouver

Medicine in DR Congo · official US FDA label

Erythromycine Stérage 250 mg

Erythromycine (erythromycin) · comprimé

Authorized in DR Congo

Want to buy it?

Not in stock in our pharmacies right now. Trouver shows when it is back near you. The reservation pages are in French.

See the pharmacies

This is a US label.

The official US FDA label for erythromycin, effective August 28, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.

Official US FDA label for erythromycin

Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.

Uses

INDICATIONS AND USAGE For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given: a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

Dosage

US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.

DOSAGE AND ADMINISTRATION In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

Side effects

ADVERSE REACTIONS The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Where to find it in DR Congo

Not in stock in our pharmacies right now

Stock changes with every sale. Search by substance: a medicine with the same composition may be available.

Composition

SubstanceStrengthATC code
Erythromycine (erythromycin)250 mg—

Marketing authorization in DR Congo

From the register of the ACOREP (the Congolese pharmaceutical regulatory authority).

  • Authorization number

    MS.1253/10/05/DGM/0946/2021

    Valid from July 5, 2021 until July 5, 2026

    Holder
    MEDICO PLUS Av. Marché n° 1106, commune de Gombe, ville de Kinshasa, R.D Congo
    Manufacturer
    Savorite Pharmaceuticals 703, Atlantis Heights, Sarabhai Compound, Vadiwadi Roda, Alkapuri390007, Vadodora (Gujarat), India
    Country
    Inde

Sources

  • ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
  • ●English names of substances: RxNorm, U.S. National Library of Medicine.
  • ●Marketing authorizations: register of the ACOREP, DR Congo, version of February 4, 2026.

Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.